

## New Steroids from the Soft Coral *Nephthea chabroliei*

Jui-Hsin Su,<sup>1</sup> Fang-Yee Lin,<sup>1</sup> Chang-Feng Dai,<sup>2</sup> Yang-Chang Wu,<sup>3</sup>  
Chi-Hsin Hsu,<sup>1,4</sup> and Jyh-Horng Sheu<sup>\*1,4</sup>

<sup>1</sup>Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan

<sup>2</sup>Institute of Oceanography, National Taiwan University, Taipei 112, Taiwan

<sup>3</sup>Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807, Taiwan

<sup>4</sup>Asian Pacific Ocean Research Center, National Sun Yat-sen University, Kaohsiung 804, Taiwan


Received May 23, 2007; E-mail: sheu@mail.nsysu.edu.tw

Six new steroids, chabrolosteroids D–I (**1**–**6**), were isolated from the organic extract of a Taiwanese soft coral *Nephthea chabroliei*. The structures of these metabolites were determined on the basis of extensive spectroscopic analysis. Metabolite **6** was found to exhibit weak cytotoxicity against the growth of Hep 3B and A-549 cell lines.

In our previous studies, we have isolated from the soft coral *Nephthea chabroliei* Audouin (Alcyonacea, Nephthedae) 25 new natural products, including eighteen meroditerpenoids,<sup>1–3</sup> three steroids,<sup>4</sup> two C<sub>18</sub> terpenoid-related carboxylic acids,<sup>3</sup> and two sesquiterpenoids.<sup>3</sup> During our continuing studies on the chemical constituents of *N. chabroliei*, six new steroids, chabrolosteroids D–I (**1**–**6**) (Chart 1), were isolated. We describe herein the isolation, structure elucidation, and biological activity of these new metabolites.

*N. chabroliei* was collected off the coast of Pingtung County, southern Taiwan, and extracted exhaustively with EtOH. After evaporation of the solvent, the residue of EtOH extract was triturated sequentially with *n*-hexane, and then with EtOAc. The EtOAc soluble part was subjected to Si gel column chromatography (CC) and eluted with solvent mixtures of increasing polarity. By the examination of the <sup>1</sup>H NMR spectra of the fractions eluted, two fractions containing steroids, as shown by the appearance of the signals of C-18 and C-19 methyl protons resonating at 0.74–1.23 ppm, were selected and further purified by normal phase HPLC to afford **1**–**6** (see Experimental section). All compounds were obtained as white powders.


Chabrolosteroid D (**1**) was found to have a molecular formula of C<sub>28</sub>H<sub>42</sub>O<sub>4</sub> on the basis of the HR-ESI-MS spectrum (*m/z* 443.3158 [M + H]<sup>+</sup>) and NMR spectra (Tables 1 and 2). The IR spectrum of **1** showed absorption bands characteristic of hydroxy (3366 cm<sup>−1</sup>) and carbonyl (1708 and 1680 cm<sup>−1</sup>) groups. The <sup>1</sup>H NMR spectral data (Table 1) of **1** showed the presence of one olefinic methine proton ( $\delta$  5.74, s), two olefinic methylene protons ( $\delta$  4.78 and 4.71, each s), one oxymethine proton ( $\delta$  4.14, t, *J* = 7.5 Hz), and four methyls ( $\delta$  1.16, s; 1.02, d, *J* = 7.0 Hz; 1.01, d, *J* = 7.0 Hz; 0.78, s). The <sup>13</sup>C NMR data (Table 2) of **1** showed the presence of twenty-eight carbon signals, which were assigned with the aid of DEPT spectra as four methyls, nine sp<sup>3</sup> methylenes, one sp<sup>2</sup> methylene, seven sp<sup>3</sup> methines (including one oxygenated), one sp<sup>2</sup> methine, and two sp<sup>3</sup> and four sp<sup>2</sup> quaternary carbons. Above observations together with the NMR signals appearing




**1** : R<sup>1</sup> = OH, R<sup>2</sup> = H

**2** : R<sup>1</sup> = H, R<sup>2</sup> = H


**3** : R<sup>1</sup> = H, R<sup>2</sup> = OH



**4**



**5**



**6**

Chart 1.

Table 1. <sup>1</sup>H NMR Chemical Shifts for Compounds 1–6

No.	1 <sup>a)</sup>	2 <sup>b)</sup>	3 <sup>a)</sup>	4 <sup>a)</sup>	5 <sup>a)</sup>	6 <sup>a)</sup>
1	$\alpha$ : 1.65 m; $\beta$ : 1.97 m	$\alpha$ : 1.67 m; $\beta$ : 1.99 m	$\alpha$ : 1.67 m; $\beta$ : 1.97 m	$\alpha$ : 1.68 m; $\beta$ : 2.00 m	7.04 d (10.0)	$\alpha$ : 1.09 m; $\beta$ : 1.79 m
2	$\alpha$ : 2.41 m; $\beta$ : 2.34 m	2.40 m	$\alpha$ : 2.35 m; $\beta$ : 2.41 m	$\alpha$ : 2.34 m; $\beta$ : 2.40 m	6.24 d (10.0)	1.67 m
3						3.51 m
4	5.74 s	5.73 s	5.74 s	5.74 s	6.10 s	$\alpha$ : 2.29 m; $\beta$ : 2.22 m
6	$\alpha$ : 2.27 m; $\beta$ : 2.37 m	2.29 m	$\alpha$ : 2.27 m; $\beta$ : 2.38 m	$\alpha$ : 2.27 m; $\beta$ : 2.37 m	$\alpha$ : 2.37 dt (12.0, 2.5) $\beta$ : 2.47 ddd (13.5, 12.0, 5.5)	5.34 d (4.5)
7	$\alpha$ : 1.07 m; $\beta$ : 1.81 m	$\alpha$ : 1.08 m; $\beta$ : 1.86 m	$\alpha$ : 1.08 m; $\beta$ : 1.84 m	$\alpha$ : 1.06 m; $\beta$ : 1.84 m	$\alpha$ : 1.94 m; $\beta$ : 1.06 m	1.82 m
8	1.52 m	1.59 m	1.56 m	1.55 m	1.80 m	1.54 m
9	0.98 m	0.96 m	0.95 m	0.95 m	1.06 m	0.92 m
11	$\alpha$ : 1.49 m; $\beta$ : 1.37 m	1.51 m	1.54 m	$\alpha$ : 1.52 m; $\beta$ : 1.39 m	1.62 m	$\alpha$ : 1.39 m; $\beta$ : 1.47 m
12	$\alpha$ : 1.24 m; $\beta$ : 1.72 m	1.76 m	$\alpha$ : 1.50 m; $\beta$ : 1.39 m	$\alpha$ : 1.12 m; $\beta$ : 1.84 m	$\alpha$ : 1.46 m; $\beta$ : 1.40 m	1.71 m
14	1.44 m	1.09 m	1.74 m	1.10 m	1.73 m	1.02 m
15	1.74 m; 1.62 m	1.68 m; 1.14 m	1.72 m; 1.14 m	1.70 m; 1.18 m	1.04 m; 1.74 m	1.67 m; 1.12 m
16	4.14 t (7.5) <sup>c)</sup>	1.90 m; 1.32 m	1.78 m	2.06 m; 1.38 m	1.80 m	1.89 m; 1.30 m
17	1.64 m	1.70 m		1.90 m		1.65 m
18	0.78 s	0.77 s	0.85 s	0.81 s	0.88 s	0.74 s
19	1.16 s	1.16 s	1.17 s	1.18 s	1.23 s	0.99 s
20	2.48 m	2.31 m	2.59 m	2.42 m	2.63 m	2.28 m
21						
22	1.81 m; 1.94 m	1.72 m	1.77 m; 1.98 m	3.89 br s	1.78 m; 1.97 m	1.98 m
23	2.07 m; 2.00 m	2.01 m	2.00 m	2.29 m; 2.24 m	2.02 m; 2.06 m	1.50 m
24						
25	2.22 m	2.24 m	2.21 m	2.22 m	2.22 m	2.20 m
26	1.02 d (7.0)	1.01 d (6.7)	1.01 d (7.0)	1.04 d (7.0)	1.03 d (7.0)	1.01 d (6.5)
27	1.01 d (7.0)	1.00 d (6.7)	1.02 d (7.0)	1.06 d (7.0)	1.01 d (7.0)	1.00 d (7.0)
28	4.78 s; 4.71 s	4.67 s; 4.76 s	4.71 s; 4.78 s	4.97 s; 4.83 s	4.78 s; 4.71 s	4.67 s; 4.75 s

a) Spectra recorded at 500 MHz in CDCl<sub>3</sub>. b) 300 MHz in CDCl<sub>3</sub>. c) *J* values (in Hz) parenthese.Table 2. <sup>13</sup>C NMR Chemical Shifts for Compounds 1–6

No.	1 <sup>a)</sup>		2 <sup>b)</sup>		3 <sup>a)</sup>		4 <sup>a)</sup>		5 <sup>a)</sup>		6 <sup>a)</sup>	
1	35.6	(CH <sub>2</sub> ) <sup>c)</sup>	35.8	(CH <sub>2</sub> )	35.7	(CH <sub>2</sub> )	35.7	(CH <sub>2</sub> )	151.6	(CH)	37.3	(CH <sub>2</sub> )
2	33.9	(CH <sub>2</sub> )	34.0	(CH <sub>2</sub> )	33.8	(CH <sub>2</sub> )	33.9	(CH <sub>2</sub> )	127.4	(CH)	30.6	(CH <sub>2</sub> )
3	199.5	(C)	199.7	(C)	199.8	(C)	199.8	(C)	186.6	(C)	71.7	(CH)
4	124.0	(CH)	123.9	(CH)	123.8	(CH)	123.8	(CH)	123.8	(CH)	42.2	(CH <sub>2</sub> )
5	171.0	(C)	171.5	(C)	171.7	(C)	171.5	(C)	169.7	(C)	140.7	(C)
6	32.7	(CH <sub>2</sub> )	32.9	(CH <sub>2</sub> )	32.9	(CH <sub>2</sub> )	32.8	(CH <sub>2</sub> )	32.9	(CH <sub>2</sub> )	121.5	(CH)
7	31.8	(CH <sub>2</sub> )	32.0	(CH <sub>2</sub> )	31.9	(CH <sub>2</sub> )	31.9	(CH <sub>2</sub> )	33.6	(CH <sub>2</sub> )	31.6	(CH <sub>2</sub> )
8	34.9	(CH)	35.6	(CH)	35.7	(CH)	35.6	(CH)	35.6	(CH)	31.8	(CH)
9	53.5	(CH)	53.8	(CH)	53.3	(CH)	53.8	(CH)	51.8	(CH)	50.1	(CH)
10	38.5	(C)	38.6	(C)	38.5	(C)	38.6	(C)	43.6	(C)	36.5	(C)
11	20.5	(CH <sub>2</sub> )	21.0	(CH <sub>2</sub> )	20.8	(CH <sub>2</sub> )	20.8	(CH <sub>2</sub> )	22.6	(CH <sub>2</sub> )	21.0	(CH <sub>2</sub> )
12	37.5	(CH <sub>2</sub> )	37.4	(CH <sub>2</sub> )	30.6	(CH <sub>2</sub> )	36.9	(CH <sub>2</sub> )	30.5	(CH <sub>2</sub> )	37.4	(CH <sub>2</sub> )
13	43.8	(C)	42.2	(C)	47.5	(C)	43.8	(C)	47.7	(C)	42.0	(C)
14	52.3	(CH)	55.4	(CH)	49.3	(CH)	55.4	(CH)	48.9	(CH)	56.1	(CH)
15	36.5	(CH <sub>2</sub> )	23.6	(CH <sub>2</sub> )	22.9	(CH <sub>2</sub> )	23.4	(CH <sub>2</sub> )	23.1	(CH <sub>2</sub> )	23.7	(CH <sub>2</sub> )
16	75.8	(CH)	27.2	(CH <sub>2</sub> )	36.0	(CH <sub>2</sub> )	26.9	(CH <sub>2</sub> )	36.1	(CH <sub>2</sub> )	27.1	(CH <sub>2</sub> )
17	62.0	(CH)	52.4	(CH)	84.1	(C)	48.9	(CH)	84.1	(C)	52.5	(CH)
18	13.8	(CH <sub>3</sub> )	12.1	(CH <sub>3</sub> )	14.9	(CH <sub>3</sub> )	11.6	(CH <sub>3</sub> )	15.0	(CH <sub>3</sub> )	11.9	(CH <sub>3</sub> )
19	17.3	(CH <sub>3</sub> )	17.4	(CH <sub>3</sub> )	17.3	(CH <sub>3</sub> )	17.3	(CH <sub>3</sub> )	18.7	(CH <sub>3</sub> )	19.3	(CH <sub>3</sub> )
20	45.5	(CH)	47.1	(CH)	48.9	(CH)	51.2	(CH)	48.7	(CH)	47.0	(CH)
21	180.0	(C)	181.5	(C)	180.5	(C)	176.2	(C)	178.8	(C)	181.2	(C)
22	30.2	(CH <sub>2</sub> )	30.7	(CH <sub>2</sub> )	27.5	(CH <sub>2</sub> )	68.4	(CH)	27.4	(CH <sub>2</sub> )	31.9	(CH <sub>2</sub> )
23	32.2	(CH <sub>2</sub> )	32.0	(CH <sub>2</sub> )	32.1	(CH <sub>2</sub> )	41.2	(CH <sub>2</sub> )	32.0	(CH <sub>2</sub> )	31.8	(CH <sub>2</sub> )
24	154.9	(C)	155.2	(C)	154.8	(C)	151.7	(C)	154.8	(C)	155.2	(C)
25	33.7	(CH)	33.8	(CH)	33.7	(CH)	33.5	(CH)	33.8	(CH)	33.7	(CH)
26	21.8	(CH <sub>3</sub> )	21.8	(CH <sub>3</sub> )	21.9	(CH <sub>3</sub> )	21.9	(CH <sub>3</sub> )	21.9	(CH <sub>3</sub> )	21.8	(CH <sub>3</sub> )
27	21.7	(CH <sub>3</sub> )	21.9	(CH <sub>3</sub> )	21.7	(CH <sub>3</sub> )	21.6	(CH <sub>3</sub> )	21.7	(CH <sub>3</sub> )	21.7	(CH <sub>3</sub> )
28	107.1	(CH <sub>2</sub> )	107.0	(CH <sub>2</sub> )	107.1	(CH <sub>2</sub> )	110.5	(CH <sub>2</sub> )	107.1	(CH <sub>2</sub> )	106.8	(CH <sub>2</sub> )

a) Spectra recorded at 125 MHz in CDCl<sub>3</sub>. b) 75 MHz in CDCl<sub>3</sub>. c) Attached protons were deduced by DEPT experiments.

at  $\delta_C$  199.5 (C), 171.0 (C), 124.0 (CH), 38.5 (C), 35.6 (CH<sub>2</sub>), and 33.9 (CH<sub>2</sub>), and the UV absorption at 242 nm, **1** was elucidated to contain an  $\alpha,\beta$ -unsaturated carbonyl structural unit in ring A.<sup>5</sup> The presence of a carboxy group was also determined from the IR spectra (1708 cm<sup>-1</sup>) and <sup>13</sup>C chemical shifts ( $\delta_C$  180.0). Careful analysis of the <sup>1</sup>H-<sup>1</sup>H COSY and HMBC spectra (Fig. 1) allowed us to determine the position of the hydroxy and the carboxy group to be at C-16 and C-20, respectively. Detailed analysis of the <sup>1</sup>H-<sup>1</sup>H COSY and HMBC correlations (Fig. 1) further established the planar structure of **1**. In the NOESY spectrum of **1** (Fig. 2), the NOE correlations between H-16 and H<sub>3</sub>-18, H-20, and H-22 ( $\delta$  1.94) as well as between H-8 and both H<sub>3</sub>-18 and H<sub>3</sub>-19 indicated that these protons adopt a  $\beta$ -orientation. This was further supported comparing them to NOE correlations displayed between the protons at C-16, C-18, and C-20 of some known compounds.<sup>6</sup> On the basis of above findings and other detailed NOE correlations, the structure of **1** was fully established as a rarely found 21-carboxysteroid.<sup>7-9</sup>

Chabrolosteroid E (**2**) was also obtained as a white powder. The HR-ESI-MS ( $m/z$  427.3209, [M + H]<sup>+</sup>) and NMR data of **2** indicated a molecular formula of C<sub>28</sub>H<sub>42</sub>O<sub>3</sub>. Its UV ( $\lambda_{\max}$  240 nm, log  $\epsilon$  3.77), IR ( $\nu_{\max}$  1674 cm<sup>-1</sup>), and <sup>1</sup>H and <sup>13</sup>C NMR data (Tables 1 and 2) are very similar to those of **1** except that the NMR signals of H-16 and C-16 were shifted significantly upfield (from  $\delta_H$  4.14 to 1.90 and 1.32 ppm and from  $\delta_C$  75.8 to 27.2 ppm, respectively) when compared to those of **1**. This result showed the hydroxymethine at C-16 in **1** was replaced by a methylene in **2**. These observations were further confirmed with the assistance of 2D NMR (<sup>1</sup>H-<sup>1</sup>H COSY and HMBC) experiments and by comparing of the NMR data to those of a known compound.<sup>7</sup> From these results, **2** was the 16-deoxy derivative of **1**.

Chabrolosteroid F (**3**) was found to possess the same molecular formula, C<sub>28</sub>H<sub>42</sub>O<sub>4</sub>, as that of **1** based on the HR-ESI-MS ( $m/z$  443.3163 [M + H]<sup>+</sup>) and NMR data (Tables 1 and 2). The <sup>1</sup>H and <sup>13</sup>C NMR spectral data of **3** are similar to those of **2** and showed the presence of an additional hydroxy group as compared to **2**. Confirmation for the position of the hydroxy group at C-17 came from HMBC correlations observed from H-14 ( $\delta_H$  1.74, m), H<sub>2</sub>-16 ( $\delta_H$  1.78, m), H<sub>3</sub>-18 ( $\delta_H$  0.85, s), and H-20 ( $\delta_H$  2.59, m) to C-17 ( $\delta_C$  84.1, C). The relative stereochemistry of compound **3** was established by comparing the NOESY correlations to those of **2**. The NOE interactions observed between H<sub>3</sub>-18 and H-20 confirmed that there is an  $\alpha$ -hydroxy at C-17. Moreover, the  $\alpha$ -orientation of 17-OH was further confirmed by the lower field chemical shift of H-14 ( $\delta_H$  1.74, m). On the basis of the above results, the structure of compound **3** was established.

Chabrolosteroid G (**4**) was found to be more polar than compounds **1-3** and was isolated as a white powder. It possessed the same molecular formula (C<sub>28</sub>H<sub>42</sub>O<sub>4</sub>) as those of **1** and **3** as determined from HR-ESI-MS. The UV ( $\lambda_{\max}$  242 nm, log  $\epsilon$  3.91), and IR ( $\nu_{\max}$  1684 cm<sup>-1</sup>) absorptions suggested the presence of an  $\alpha,\beta$ -unsaturated carbonyl system in **4**. Comparison of the <sup>1</sup>H and <sup>13</sup>C NMR data (Tables 1 and 2) of both compounds showed that the structure of **4** should be very close to that of **2**, except for the signals assigned to C-22, where a methylene ( $\delta_H$  1.72, 2H, m;  $\delta_C$  30.7) in **2** was replaced by a




Fig. 1. Selective <sup>1</sup>H-<sup>1</sup>H COSY and HMBC correlations for **1**, **5**, and **6**.

hydroxymethine ( $\delta_H$  3.89, 1H, br s;  $\delta_C$  68.4) in **4**. The observed COSY between H-22 and H<sub>2</sub>-23 and HMBC correlation between H<sub>2</sub>-23 to C-22 and C-20 further confirmed that a hydroxy group is present at C-22 location of the hydroxy group. Thus, **4** is the 22-hydroxy derivative of **2**.

Chabrolosteroid H (**5**) had a molecular formula of C<sub>28</sub>H<sub>40</sub>O<sub>4</sub> as determined by HR-ESI-MS. The NMR signals appearing at  $\delta_H$  7.04/ $\delta_C$  151.6; 6.24/127.4; 6.10/123.8; 186.6 (C) 169.7 (C), the IR absorption at 1658 cm<sup>-1</sup>, and UV maximum at 248 nm were assigned to a cross-conjugated dienone system by comparing to similar metabolites.<sup>10</sup> Furthermore, the proton sequence from H-1 to H-2 and the HMBC spectrum (Fig. 1) showed long range correlations from H-1 to C-3, C-5, C-10; H-2 to C-4; H-4 to C-10 and H<sub>3</sub>-19 to C-1, C-5, C-9, C-10, further supporting this structural unit in the A ring of **5**. It was found that the remaining partial structures, including rings B, C, and D, and the side chain of **5**, are identical to those of **3** by comparison of the related 1D (<sup>1</sup>H and <sup>13</sup>C) and 2D NMR data, particularly the <sup>1</sup>H-<sup>1</sup>H COSY and HMBC correlations. Therefore, the structure of steroid **5** was established as the 1,2-dehydro derivative of **3**.

The related metabolite, chabrolosteroid I (**6**), had a molecular formula C<sub>28</sub>H<sub>44</sub>O<sub>3</sub> as indicated by the HR-ESI-MS ( $m/z$  429.3365, [M + H]<sup>+</sup>) and NMR data (Tables 1 and 2). The interpretation of the <sup>1</sup>H-<sup>1</sup>H COSY and HMBC correlations (Fig. 1) were employed to determine the positions of the hydroxy, one double bond in the ring, and the carboxyl group to be at C-3, C-5/C-6, and C-20, respectively. Thus, the




Fig. 2. Selective NOESY correlations for **1** and **6**.

planar structure of **6** was established. The stereochemistry of **6** was further determined by analyzing the NOESY correlations (Fig. 2). Moreover, a comparison of the NMR data between **6** and **2** confirmed that in both compounds, rings C and D as well as the side chain have the same structure. On the basis of above analysis, the structure of **6** was unambiguously established. Compounds **2** and **6** did not possess a hydroxy group at both D-ring and side chain, and the other steroids (**1** and **3–5**) were found to be the rarely discovered 21-carboxysteroids with hydroxy groups at C-16, C-17, or C-22, respectively.

The cytotoxicity of compounds **1–6** against the proliferation of a limited panel of cancer cell lines, including human hepatocellular carcinomas (Hep G2 and Hep 3B), human breast carcinomas (MCF-7 and MDA-MB-231), and a human lung carcinoma (A-549), was studied. The results showed that **1–5** are not cytotoxic toward the above cancer cells. Metabolite **6** exhibited a moderate to weak cytotoxicity toward Hep 3B ( $IC_{50}$   $15.6 \mu\text{g mL}^{-1}$ ) and A-549 ( $IC_{50}$   $17.8 \mu\text{g mL}^{-1}$ ) cancer cell lines.

## Experimental

**General Experimental Procedures.** The IR spectra were recorded on a Jasco FT-5300 infrared spectrophotometer. UV spectra were recorded on a Hitachi U-3210 UV spectrophotometer. NMR spectra were recorded on a Bruker AVANCE DPX300 FT-NMR at 300 MHz for  $^1\text{H}$  and 75 MHz for  $^{13}\text{C}$  or on a Varian Unity INOVA 500 FT-NMR at 500 MHz for  $^1\text{H}$  and 125 MHz for  $^{13}\text{C}$ , in  $\text{CDCl}_3$ . Low-resolution MS data were obtained by ESI on a Bruker APEX II mass spectrometer. HRMS were recorded on ESI on a Bruker APEX II mass spectrometer. Silica gel (Merck, 230–400 mesh) was used for column chromatography. High-performance liquid chromatography (HPLC) was performed on a Hitachi L-7100 apparatus equipped with a Bischoff refractive index detector, or a Hitachi L-7400 UV detector and with the Merck Hibar Si-60 column ( $250 \times 21 \text{ mm}$ ,  $7 \mu\text{m}$ ).

**Animal Material.** The soft coral *N. chabroliei* was collected by hand using SCUBA off the coast of Pingtung County, located in southern Taiwan, in July 2001, at depths of 15–20 m and

stored in a freezer until extraction. A voucher sample (SC-64) was deposited at the Department of Marine Biotechnology and Resources, National Sun Yat-sen University.

**Extraction and Isolation.** The sliced bodies of *N. chabroliei* (1.8 kg, wet wt) were exhaustively homogenized with EtOH and filtered. The combined EtOH extract was concentrated in vacuo to afford a dark brown viscous residue (20.8 g). The residue was triturated with *n*-hexane to afford an *n*-hexane soluble fraction, and then with EtOAc. The solvent was removed from the EtOAc soluble fraction under vacuum to yield an oily residue (15.8 g), which was subjected to column chromatography on silica gel, using *n*-hexane, *n*-hexane and EtOAc mixtures of increasing polarity, and finally pure EtOAc, to yield 28 fractions. Fraction 17, eluted with *n*-hexane–EtOAc (2:1), was further separated by normal phase HPLC using *n*-hexane–acetone (5:1) to yield **2** (4.7 mg) and **6** (5.0 mg). Fraction 21, eluted with *n*-hexane–EtOAc (1:1), was further purified by normal phase HPLC using *n*-hexane–acetone (4:1) to afford **1** (5.7 mg), **3** (8.7 mg), **4** (2.1 mg), and **5** (2.2 mg), respectively.

Chabrolosteroid D (**1**): white powder; mp  $181\text{--}184^\circ\text{C}$ ;  $[\alpha]_D^{25} = +50$  (*c* 1.14,  $\text{CHCl}_3$ ); UV (MeOH)  $\lambda_{\text{max}}$  ( $\log \epsilon$ ) 242 (3.79) nm; IR (neat)  $\nu_{\text{max}}$  3366, 2935, 1708, 1680, 1386  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz) and  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 125 MHz), see Tables 1 and 2; EI-MS  $m/z$  442 (8,  $[\text{M}]^+$ ); HR-ESI-MS  $m/z$  443.3158 (calcd for  $\text{C}_{28}\text{H}_{43}\text{O}_4$ , 443.3163).

Chabrolosteroid E (**2**): white powder; mp  $179\text{--}181^\circ\text{C}$ ;  $[\alpha]_D^{25} = +59$  (*c* 1.00,  $\text{CHCl}_3$ ); UV (MeOH)  $\lambda_{\text{max}}$  ( $\log \epsilon$ ) 240 (3.77) nm; IR (neat)  $\nu_{\text{max}}$  3378, 2930, 1706, 1674, 1379  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) and  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 75 MHz), see Tables 1 and 2; ESI-MS  $m/z$  427 (100,  $[\text{M} + \text{H}]^+$ ); HR-ESI-MS  $m/z$  427.3209 (calcd for  $\text{C}_{28}\text{H}_{43}\text{O}_3$ , 427.3214).

Chabrolosteroid F (**3**): white powder; mp  $185\text{--}187^\circ\text{C}$ ;  $[\alpha]_D^{25} = +47$  (*c* 1.74,  $\text{CHCl}_3$ ); UV (MeOH)  $\lambda_{\text{max}}$  ( $\log \epsilon$ ) 240 (3.82) nm; IR (neat)  $\nu_{\text{max}}$  3420, 2939, 1703, 1680, 1380  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz) and  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 125 MHz), see Tables 1 and 2; ESI-MS  $m/z$  443 (100,  $[\text{M} + \text{H}]^+$ ); HR-ESI-MS  $m/z$  443.3163 (calcd for  $\text{C}_{28}\text{H}_{43}\text{O}_4$ , 443.3163).

Chabrolosteroid G (**4**): white powder; mp  $190\text{--}192^\circ\text{C}$ ;  $[\alpha]_D^{25} = +84$  (*c* 1.00,  $\text{CHCl}_3$ ); UV (MeOH)  $\lambda_{\text{max}}$  ( $\log \epsilon$ ) 242 (3.91) nm; IR (neat)  $\nu_{\text{max}}$  3422, 2929, 1716, 1684, 1338  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz) and  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 125 MHz), see Tables 1 and 2; ESI-MS  $m/z$  465 (80,  $[\text{M} + \text{Na}]^+$ ); HR-ESI-MS  $m/z$  465.2978 (calcd for  $\text{C}_{28}\text{H}_{42}\text{O}_4\text{Na}$ , 465.2980).

Chabrolosteroid H (**5**): white powder; mp  $188\text{--}190^\circ\text{C}$ ;  $[\alpha]_D^{25} = +37$  (*c* 0.80,  $\text{CHCl}_3$ ); UV (MeOH)  $\lambda_{\text{max}}$  ( $\log \epsilon$ ) 248 (3.90) nm; IR (neat)  $\nu_{\text{max}}$  3423, 2935, 1714, 1658, 1361  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz) and  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 125 MHz), see Tables 1 and 2; ESI-MS  $m/z$  441 (100,  $[\text{M} + \text{H}]^+$ ); HR-ESI-MS  $m/z$  441.3004 (calcd for  $\text{C}_{28}\text{H}_{41}\text{O}_4$ , 441.3005).

Chabrolosteroid I (**6**): white powder; mp  $204\text{--}207^\circ\text{C}$ ;  $[\alpha]_D^{25} = -77$  (*c* 0.94,  $\text{CHCl}_3$ ); IR (neat)  $\nu_{\text{max}}$  3420, 2934, 1699, 1643, 1377  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 500 MHz) and  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 125 MHz), see Tables 1 and 2; ESI-MS  $m/z$  429 (100,  $[\text{M} + \text{H}]^+$ ); HR-ESI-MS  $m/z$  429.3365 (calcd for  $\text{C}_{28}\text{H}_{45}\text{O}_3$ , 429.3371).

**Cytotoxicity Testing.** Cytotoxicity assays of compounds **1–6** were performed using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] colorimetric method.<sup>11</sup>

Financial support was provided by Ministry of Education (No. C030313) and National Science Council of Taiwan (No. NSC 95-2113-M-110-011-MY3) awarded to J.-H. Sheu.

**References**

- 1 J.-H. Sheu, J.-H. Su, P.-J. Sung, G.-H. Wang, C.-F. Dai, *J. Nat. Prod.* **2004**, 67, 2048.
- 2 J.-H. Su, A. F. Ahmed, P.-J. Sung, Y.-C. Wu, J.-H. Sheu, *J. Nat. Prod.* **2005**, 68, 1651.
- 3 J.-H. Su, C.-F. Dai, H.-H. Huang, Y.-C. Wu, P.-J. Sung, C.-H. Hsu, J.-H. Sheu, *Chem. Pharm. Bull.* **2007**, 55, 594.
- 4 J.-H. Su, F.-Y. Lin, H.-C. Huang, C.-F. Dai, Y.-C. Wu, W.-P. Hu, C.-H. Hsu, J.-H. Sheu, *Tetrahedron* **2007**, 63, 703.
- 5 J.-M. Oger, P. Richomme, J. Bruneton, H. Guinaudeau, T. Sevenet, C. Debitus, *J. Nat. Prod.* **1991**, 54, 273.
- 6 J. Saez, W. Cardona, D. Espinal, S. Blair, J. Mesa, M. Bocar, A. Jossang, *Tetrahedron* **1998**, 54, 10771.
- 7 A. F. Ahmed, M.-H. Wu, Y.-C. Wu, C.-F. Dai, J.-H. Sheu, *J. Chin. Chem. Soc.* **2006**, 53, 489.
- 8 M. Kobayashi, B. Haribabu, V. Anjaneyulu, *Chem. Pharm. Bull.* **1992**, 40, 233.
- 9 J. R. Carney, W. Y. Yoshida, P. J. Scheuer, *J. Org. Chem.* **1992**, 57, 6637.
- 10 C.-Y. Duh, A. H. El-Gamal, P.-Y. Song, S.-K. Wang, C.-F. Dai, *J. Nat. Prod.* **2004**, 67, 1650.
- 11 T. Mosmann, *J. Immunol. Methods* **1983**, 65, 55.